XOMA Royalty Acquires Pulmokine for $20 Million Adding the Royalty and Milestone Interest in Seralutinib, a Phase 3 Asset, to Its Portfolio
Provided By GlobeNewswire
Last update: Dec 2, 2024
Seralutinib becomes XOMA Royalty’s seventh Phase 3 royalty asset, further building the late-stage pipeline beyond its six current commercial royalty assets
Read more at globenewswire.comXOMA ROYALTY CORP - XOMA 8 5/8 PERP
NASDAQ:XOMAP (12/19/2025, 8:22:20 PM)
After market: 26.07 -0.5 (-1.86%)26.565
-0.23 (-0.88%)
25.39
+0.49 (+1.97%)
XOMA ROYALTY CORP - XOMA 8 3/8 PERP
NASDAQ:XOMAO (12/19/2025, 8:22:20 PM)
25.59
+0.14 (+0.55%)
Find more stocks in the Stock Screener
